Rectal Cancer Clinical Practice Guidelines in Oncology
NCCN Categories of Evidence and Consensus
Category 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is uniform NCCN consensus.
Category 2A: The recommendation is based on lower-level evidence and there is uniform NCCN consensus.
Category 2B: The recommendation is based on lower-level evidence and there is nonuniform NCCN consensus (but no major disagreement).
Category 3: The recommendation is based on any level of evidence but reflects major disagreement.
All recommendations are category 2A unless otherwise noted.
Clinical trials: The NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Overview
In 2009 an estimated 40,870 new cases of rectal cancer will occur in the United States (23,580 cases in men; 17,290 cases in women). During the same year, an estimated 49,920 people will die from rectal and colon cancers.1 Although colorectal cancer is ranked as the fourth most frequently diagnosed cancer and the second leading cause of cancer death in the United States, mortality from colorectal cancer has decreased during the past 30 years. This decrease may be due to earlier diagnosis through screening and better treatment modalities.
The recommendations in these clinical practice guidelines are classified as category 2A except where noted, meaning that there is uniform NCCN consensus, based on lower-level evidence (including...
BonelliL, MartinesH, ConioM. Family history of colorectal cancer as a risk factor for benign and malignant tumours of the large bowel. A case-control study. Int J Cancer1988;41:513–517.
BonelliLMartinesHConioM. Family history of colorectal cancer as a risk factor for benign and malignant tumours of the large bowel. A case-control study. Int J Cancer1988;41:513–517.
)| false
AhsanH, NeugutAI, GarbowskiGC. Family history of colorectal adenomatous polyps and increased risk for colorectal cancer. Ann Intern Med1998;128:900–905.
AhsanHNeugutAIGarbowskiGC. Family history of colorectal adenomatous polyps and increased risk for colorectal cancer. Ann Intern Med1998;128:900–905.
)| false
GreeneFL, StewartAK, NortonHJ. A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients. Ann Surg2002;236:416–421; discussion 421.
GreeneFLStewartAKNortonHJ. A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients. Ann Surg2002;236:416–421; discussion 421.
)| false
ComptonCC. Updated protocol for the examination of specimens from patients with carcinomas of the colon and rectum, excluding carcinoid tumors, lymphomas, sarcomas, and tumors of the vermiform appendix: a basis for checklists. Cancer Committee. Arch Pathol Lab Med2000;124:1016–1025.
ComptonCC. Updated protocol for the examination of specimens from patients with carcinomas of the colon and rectum, excluding carcinoid tumors, lymphomas, sarcomas, and tumors of the vermiform appendix: a basis for checklists. Cancer Committee. Arch Pathol Lab Med2000;124:1016–1025.
)| false
ComptonCC. Key issues in reporting common cancer specimens: problems in pathologic staging of colon cancer. Arch Pathol Lab Med2006;130:318–324.
ComptonCC. Key issues in reporting common cancer specimens: problems in pathologic staging of colon cancer. Arch Pathol Lab Med2006;130:318–324.
)| false
LaiLL, FullerCD, KachnicLA, ThomasCRJr. Can pelvic radiotherapy be omitted in select patients with rectal cancer?Semin Oncol2006;33(Suppl 11):S70–74.
LaiLLFullerCDKachnicLAThomasCRJr. Can pelvic radiotherapy be omitted in select patients with rectal cancer?Semin Oncol2006;33(Suppl 11):S70–74.
)| false
NagtegaalID, MarijnenCA, KranenbargEK. Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit. Am J Surg Pathol2002;26:350–357.
NagtegaalIDMarijnenCAKranenbargEK. Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit. Am J Surg Pathol2002;26:350–357.
)| false
WibeA, RendedalPR, SvenssonE. Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. Br J Surg2002;89:327–334.
WibeARendedalPRSvenssonE. Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. Br J Surg2002;89:327–334.
)| false
StocchiL, NelsonH, SargentDJ. Impact of surgical and pathologic variables in rectal cancer: a United States community and cooperative group report. J Clin Oncol2001;19:3895–3902.
StocchiLNelsonHSargentDJ. Impact of surgical and pathologic variables in rectal cancer: a United States community and cooperative group report. J Clin Oncol2001;19:3895–3902.
)| false
Glynne-JonesR, MawdsleyS, NovellJR. The clinical significance of the circumferential resection margin following preoperative pelvic chemo-radiotherapy in rectal cancer: why we need a common language. Colorectal Dis2006;8:800–807.
Glynne-JonesRMawdsleySNovellJR. The clinical significance of the circumferential resection margin following preoperative pelvic chemo-radiotherapy in rectal cancer: why we need a common language. Colorectal Dis2006;8:800–807.
)| false
MawdsleyS, Glynne-JonesR, GraingerJ. Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival?Int J Radiat Oncol Biol Phys2005;63:745–752.
MawdsleySGlynne-JonesRGraingerJ. Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival?Int J Radiat Oncol Biol Phys2005;63:745–752.
)| false
NewlandRC, DentOF, LyttleMN. Pathologic determinants of survival associated with colorectal cancer with lymph node metastases. A multivariate analysis of 579 patients. Cancer1994;73:2076–2082.
NewlandRCDentOFLyttleMN. Pathologic determinants of survival associated with colorectal cancer with lymph node metastases. A multivariate analysis of 579 patients. Cancer1994;73:2076–2082.
)| false
PocardM, PanisY, MalassagneB. Assessing the effectiveness of mesorectal excision in rectal cancer: prognostic value of the number of lymph nodes found in resected specimens. Dis Colon Rectum1998;41:839–845.
PocardMPanisYMalassagneB. Assessing the effectiveness of mesorectal excision in rectal cancer: prognostic value of the number of lymph nodes found in resected specimens. Dis Colon Rectum1998;41:839–845.
)| false
WichmannMW, MullerC, MeyerG. Effect of preoperative radiochemotherapy on lymph node retrieval after resection of rectal cancer. Arch Surg2002;137:206–210.
WichmannMWMullerCMeyerG. Effect of preoperative radiochemotherapy on lymph node retrieval after resection of rectal cancer. Arch Surg2002;137:206–210.
)| false
BaxterNN, MorrisAM, RothenbergerDA, TeppeJE. Impact of pre-operative radiation for rectal cancer on subsequent lymph node evaluation: population based analysis. Int J Rad Oncol Biol Phys2005;61:426–431.
BaxterNNMorrisAMRothenbergerDATeppeJE. Impact of pre-operative radiation for rectal cancer on subsequent lymph node evaluation: population based analysis. Int J Rad Oncol Biol Phys2005;61:426–431.
)| false
MeyersMO, HollisDR, MayerRJ. Ratio of metastatic to examined lymph nodes is a powerful predictor of overall survival in rectal cancer: an analysis of Intergroup 0114 [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 4008.
MeyersMOHollisDRMayerRJ. Ratio of metastatic to examined lymph nodes is a powerful predictor of overall survival in rectal cancer: an analysis of Intergroup 0114 [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 4008.
)| false
TurnerRR, NoraDT, TrochaSD, BilchikAJ. Colorectal carcinoma nodal staging. Frequency and nature of cytokeratin-positive cells in sentinel and nonsentinel lymph nodes. Arch Pathol Lab Med2003;127:673–679.
TurnerRRNoraDTTrochaSDBilchikAJ. Colorectal carcinoma nodal staging. Frequency and nature of cytokeratin-positive cells in sentinel and nonsentinel lymph nodes. Arch Pathol Lab Med2003;127:673–679.
)| false
WoodTF, NoraDT, MortonDL. One hundred consecutive cases of sentinel node mapping in early colorectal carcinoma. Detection of micrometastasis. J Gastrointest Surg2002;6:322–330.
WoodTFNoraDTMortonDL. One hundred consecutive cases of sentinel node mapping in early colorectal carcinoma. Detection of micrometastasis. J Gastrointest Surg2002;6:322–330.
)| false
NouraS, YamamotoH, MiyakeY. Immunohistochemical assessment of localization and frequency of micrometastases in lymph nodes of colorectal cancer. Clin Cancer Res2002;8:759–767.
NouraSYamamotoHMiyakeY. Immunohistochemical assessment of localization and frequency of micrometastases in lymph nodes of colorectal cancer. Clin Cancer Res2002;8:759–767.
)| false
YasudaK, AdachiY, ShiraishiN. Pattern of lymph node micrometastasis and prognosis of patients with colorectal cancer. Ann Surg Oncol2001;8:300–304.
YasudaKAdachiYShiraishiN. Pattern of lymph node micrometastasis and prognosis of patients with colorectal cancer. Ann Surg Oncol2001;8:300–304.
)| false
BraatAE, OosterhuisJW, MollFC. Sentinel node detection after preoperative short-course radiotherapy in rectal carcinoma is not reliable. Br J Surg2005;92:1533–1538.
BraatAEOosterhuisJWMollFC. Sentinel node detection after preoperative short-course radiotherapy in rectal carcinoma is not reliable. Br J Surg2005;92:1533–1538.
)| false
AmadoRG, WolfM, PeetersM. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol2008;26:1626–1634.
AmadoRGWolfMPeetersM. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol2008;26:1626–1634.
)| false
Khambata-FordS, GarrettCR, MeropolNJ. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol2007;25:3230–3237.
Khambata-FordSGarrettCRMeropolNJ. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol2007;25:3230–3237.
)| false
De RoockW, PiessevauxH, De SchutterJ. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol2008;19:508–515.
De RoockWPiessevauxHDe SchutterJ. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol2008;19:508–515.
)| false
PuntCJ, TolJ, RodenburgCJ. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract LBA 4011.
PuntCJTolJRodenburgCJ. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract LBA 4011.
)| false
BokemeyerC, BondarenkoI, MakhsonA. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol2009;27:663–771.
BokemeyerCBondarenkoIMakhsonA. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol2009;27:663–771.
)| false
TejparS, PeetersM, HumbletY. Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer, treated with irinotecan and escalating doses of cetuximab: the EVEREST experience (preliminary data) [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 4001.
TejparSPeetersMHumbletY. Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer, treated with irinotecan and escalating doses of cetuximab: the EVEREST experience (preliminary data) [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 4001.
)| false
Van CutsemE, Henning-KohneC, HitreE. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med2009; 36014:1408–1417.
Van CutsemEHenning-KohneCHitreE. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med2009; 36014:1408–1417.
)| false
LièvreA, BachetJB, BoigeV. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol2008;26:374–379.
LièvreABachetJBBoigeV. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol2008;26:374–379.
)| false
LievreA, BachetJB, BoigeV. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treatment with cetuximab. J Clin Oncol2008;26:374–379.
LievreABachetJBBoigeV. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treatment with cetuximab. J Clin Oncol2008;26:374–379.
)| false
ArtaleS, Sartore-BianchiA, VeroneseSM. Mutations in KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol2008;26:4217–4219.
ArtaleSSartore-BianchiAVeroneseSM. Mutations in KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol2008;26:4217–4219.
)| false
Etienne-GrimaldiMC, FormentoJL, FrancoualM. KRAS mutations in treatment outcome in colorectal cancer in patients receiving exclusive fluoropyrimidine. Clin Cancer Res2008;14:4830–4835.
Etienne-GrimaldiMCFormentoJLFrancoualM. KRAS mutations in treatment outcome in colorectal cancer in patients receiving exclusive fluoropyrimidine. Clin Cancer Res2008;14:4830–4835.
)| false
KapiteijnE, MarijnenCA, NagtegaalID. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med2001;345:638–646.
KapiteijnEMarijnenCANagtegaalID. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med2001;345:638–646.
)| false
SchoellhammerHF, GregorianAC, SarkisyanGG, PetrieBA. How important is rigid proctosigmoidoscopy in localizing rectal cancer. Am J Surg2008;186:904–908.
SchoellhammerHFGregorianACSarkisyanGGPetrieBA. How important is rigid proctosigmoidoscopy in localizing rectal cancer. Am J Surg2008;186:904–908.
)| false
BipatS, GlasAS, SlorsFJ. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging—a meta-analysis. Radiology2004;232:773–783.
BipatSGlasASSlorsFJ. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging—a meta-analysis. Radiology2004;232:773–783.
)| false
LahayeMJ, EngelenSM, NelemansPJ. Imaging for predicting the risk factors—the circumferential resection margin and nodal disease—of local recurrence in rectal cancer: a meta-analysis. Semin Ultrasound CT MR2005;26:259–268.
LahayeMJEngelenSMNelemansPJ. Imaging for predicting the risk factors—the circumferential resection margin and nodal disease—of local recurrence in rectal cancer: a meta-analysis. Semin Ultrasound CT MR2005;26:259–268.
)| false
Beets-TanRG, VliegenRF, BeetsGL. Magnetic resonance imaging of rectal cancer: what radiation oncologists need to know. Front Radiat Ther Oncol2004;38:1–12.
Beets-TanRGVliegenRFBeetsGL. Magnetic resonance imaging of rectal cancer: what radiation oncologists need to know. Front Radiat Ther Oncol2004;38:1–12.
)| false
YouYN, BaxterNN, StewartA, NelsonH. Is the increasing rate of local excision for stage I rectal cancer in the United States justified?: a nationwide cohort study from the National Cancer Database. Ann Surg2007;245:726–733.
YouYNBaxterNNStewartANelsonH. Is the increasing rate of local excision for stage I rectal cancer in the United States justified?: a nationwide cohort study from the National Cancer Database. Ann Surg2007;245:726–733.
)| false
LandmannRG, WongWD, HoepflJ. Limitations of early rectal cancer nodal staging may explain failure after local excision. Dis Colon Rectum2007;50:1520–1525.
LandmannRGWongWDHoepflJ. Limitations of early rectal cancer nodal staging may explain failure after local excision. Dis Colon Rectum2007;50:1520–1525.
)| false
JayneDG, Guillou, ThorpeH. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC trial group. J Clin Oncol2007;25:3061–3068.
JayneDGGuillouThorpeH. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC trial group. J Clin Oncol2007;25:3061–3068.
)| false
NgSS, LeungKL, LeeJF. Laparoscopic-assisted versus open abdominoperineal resection for low rectal cancer: a prospective randomized trial. Ann Surg Oncol2008;15:2418–2425.
NgSSLeungKLLeeJF. Laparoscopic-assisted versus open abdominoperineal resection for low rectal cancer: a prospective randomized trial. Ann Surg Oncol2008;15:2418–2425.
)| false
ParfittJR, DrimanDK. The total mesorectal excision specimen for rectal cancer: a review of its pathological assessment. J Clin Pathol2007;60:849–855.
ParfittJRDrimanDK. The total mesorectal excision specimen for rectal cancer: a review of its pathological assessment. J Clin Pathol2007;60:849–855.
)| false
NagetgaalID, van de VeldeCJH, van der WorpE. Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control. J Clin Oncol2002;20:1729–1734.
NagetgaalIDvan de VeldeCJHvan der WorpE. Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control. J Clin Oncol2002;20:1729–1734.
)| false
den DulkM, PutterH, ColletteL. The abdominoperineal resection itself is associated with an adverse outcome: the European experience based on a pooled analysis of five European randomised clinical trials on rectal cancer. Eur J Cancer2009;45:1175–1183.
den DulkMPutterHColletteL. The abdominoperineal resection itself is associated with an adverse outcome: the European experience based on a pooled analysis of five European randomised clinical trials on rectal cancer. Eur J Cancer2009;45:1175–1183.
)| false
SteupWH, MoriyaY, van de veldeCJH. Patterns of lymphatic spread in rectal cancer. A topographical analysis on lymph node metastases. Eur J Cancer2002;38:911–918.
SteupWHMoriyaYvan de veldeCJH. Patterns of lymphatic spread in rectal cancer. A topographical analysis on lymph node metastases. Eur J Cancer2002;38:911–918.
)| false
WagmanR, MinskyBD, CohenAM. Sphincter preservation in rectal cancer with preoperative radiation therapy and coloanal anastomosis: long term follow-up. Int J Radiat Oncol Biol Phys1998;42:51–57.
WagmanRMinskyBDCohenAM. Sphincter preservation in rectal cancer with preoperative radiation therapy and coloanal anastomosis: long term follow-up. Int J Radiat Oncol Biol Phys1998;42:51–57.
)| false
KachnicLA. Should preoperative or postoperative therapy be administered in the management of rectal cancer?Semin Oncol2006;33(Suppl 11):S64–69.
KachnicLA. Should preoperative or postoperative therapy be administered in the management of rectal cancer?Semin Oncol2006;33(Suppl 11):S64–69.
)| false
Colorectal Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet2001;358:1291–1304.
Colorectal Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet2001;358:1291–1304.
)| false
Sebag-MontefioreD, StephensRJ, SteeleR. Prooperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet2009;373:811–820.
Sebag-MontefioreDStephensRJSteeleR. Prooperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet2009;373:811–820.
)| false
GerardJP, ConroyT, BonnetainF. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol2006;24:4620–4625.
GerardJPConroyTBonnetainF. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol2006;24:4620–4625.
)| false
CeelenWP, van NieuwenhoveY, FierensK. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer (review). Cochrane Database Syst Rev2009;CD006041.
CeelenWPvan NieuwenhoveYFierensK. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer (review). Cochrane Database Syst Rev2009;CD006041.
)| false
Glynne-JonesR, Sebag-MontefioreD. Role of neoadjuvant chemotherapy in rectal cancer: interpretation of the EXPERT study. J Clin Oncol2006;24:4664–4665; author reply 4665–4666.
Glynne-JonesRSebag-MontefioreD. Role of neoadjuvant chemotherapy in rectal cancer: interpretation of the EXPERT study. J Clin Oncol2006;24:4664–4665; author reply 4665–4666.
)| false
ColletteL, BossetJF, den DulkM. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the EORTC Group. J Clin Oncol2007;25:4379–4386.
ColletteLBossetJFden DulkM. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the EORTC Group. J Clin Oncol2007;25:4379–4386.
)| false
BujkoK, KepkaL, MichalskiW, NowackiMP. Does rectal cancer shrinkage induced by preoperative radio(chemo)therapy increase the likelihood of anterior resection? A systematic review of randomised trials. Radiother Oncol2006;80:4–12.
BujkoKKepkaLMichalskiWNowackiMP. Does rectal cancer shrinkage induced by preoperative radio(chemo)therapy increase the likelihood of anterior resection? A systematic review of randomised trials. Radiother Oncol2006;80:4–12.
)| false
WongRK, TandanV, De SilvaS, FigueredoA. Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma. Cochrane Database Syst Rev2007:CD002102.
WongRKTandanVDe SilvaSFigueredoA. Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma. Cochrane Database Syst Rev2007:CD002102.
)| false
PeetersKC, van de VeldeCJ, LeerJW. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients—a Dutch colorectal cancer group study. J Clin Oncol2005;23:6199–6206.
PeetersKCvan de VeldeCJLeerJW. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients—a Dutch colorectal cancer group study. J Clin Oncol2005;23:6199–6206.
)| false
TepperJE, O’ConnellM, NiedzwieckiD. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control—final report of intergroup 0114. J Clin Oncol2002;20:1744–1750.
TepperJEO’ConnellMNiedzwieckiD. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control—final report of intergroup 0114. J Clin Oncol2002;20:1744–1750.
)| false
GundersonLL, SargentDJ, TepperJE. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol2004;22:1785–1796.
GundersonLLSargentDJTepperJE. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol2004;22:1785–1796.
)| false
JohalBS, PhangP, McGahanC. Treatment patterns and outcomes of patients with pT3N0 rectal cancer in a population-based setting [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 4039.
JohalBSPhangPMcGahanC. Treatment patterns and outcomes of patients with pT3N0 rectal cancer in a population-based setting [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 4039.
)| false
SmalleySR, BenedettiJK, WilliamsonSK. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol2006;24:3542–3547.
SmalleySRBenedettiJKWilliamsonSK. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol2006;24:3542–3547.
)| false
O’ConnellMJ, MartensonJA, WieandHS. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med1994;331:502–507.
O’ConnellMJMartensonJAWieandHS. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med1994;331:502–507.
)| false
AndreT, BoniC, Navarro. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC Trial. J Clin Oncol2009;27:3109–3116.
AndreTBoniCNavarro. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC Trial. J Clin Oncol2009;27:3109–3116.
)| false
MeyerJ, CzitoB, YinFF, WillettC. Advanced radiation therapy technologies in the treatment of rectal and anal cancer: intensity-modulated photon therapy and proton therapy. Clin Colorectal Cancer2007;6:348–356.
MeyerJCzitoBYinFFWillettC. Advanced radiation therapy technologies in the treatment of rectal and anal cancer: intensity-modulated photon therapy and proton therapy. Clin Colorectal Cancer2007;6:348–356.
)| false
American College of Radiology. Practice Guideline for Intensity-modulated radiation therapy (IMRT), 2007; Available at: http://www.acr.org/SecondaryMainMenuCategories/quality_safety/guidelines/ro/imrt.aspx. Accessed July 2009
American College of Radiology. Practice Guideline for Intensity-modulated radiation therapy (IMRT), 2007; Available at: http://www.acr.org/SecondaryMainMenuCategories/quality_safety/guidelines/ro/imrt.aspx. Accessed July 2009)| false
HahnloserD, HaddockMG, NelsonH. Intraoperative radiotherapy in the multimodality approach to colorectal cancer. Surg Oncol Clin N Am2003;12:993–1013.
HahnloserDHaddockMGNelsonH. Intraoperative radiotherapy in the multimodality approach to colorectal cancer. Surg Oncol Clin N Am2003;12:993–1013.
)| false
MooreHG, GittlemanAE, MinskyBD. Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. Dis Colon Rectum2004;47:279–286.
MooreHGGittlemanAEMinskyBD. Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. Dis Colon Rectum2004;47:279–286.
)| false
Habr-GamaA, PerezRO, ProscurshimI. Interval between surgery and neoadjuvant chemoradiation therapy for distal rectal cancer: does delayed surgery have an impact on outcome?Int J Radiat Oncol Biol Phys2008;71:1181–1188.
Habr-GamaAPerezROProscurshimI. Interval between surgery and neoadjuvant chemoradiation therapy for distal rectal cancer: does delayed surgery have an impact on outcome?Int J Radiat Oncol Biol Phys2008;71:1181–1188.
)| false
TulchinskyH, ShmuellE, GigerA. An interval > 7 weeks between neoadjuvant theapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer. Ann Surg Oncol2008;15:2661–2667.
TulchinskyHShmuellEGigerA. An interval > 7 weeks between neoadjuvant theapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer. Ann Surg Oncol2008;15:2661–2667.
)| false
TranCL, UdaniS, HoltA, ArnellT. Evaluation of safety of increased time interval between chemoradiation and resection for rectal cancer. Am J Surg2006;192:873–877.
TranCLUdaniSHoltAArnellT. Evaluation of safety of increased time interval between chemoradiation and resection for rectal cancer. Am J Surg2006;192:873–877.
)| false
WolmarkN, WieandHS, HyamsDM. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst2000;92:388–396.
WolmarkNWieandHSHyamsDM. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst2000;92:388–396.
)| false
MinskyBD, GuillemJG. Multidisciplinary management of resectable rectal cancer: new developments and controversies. Oncology (Williston Park)2008;22:1430–1437.
MinskyBDGuillemJG. Multidisciplinary management of resectable rectal cancer: new developments and controversies. Oncology (Williston Park)2008;22:1430–1437.
)| false
BensonABIII. New approaches to assessing and treating early-stage colon and rectal cancers: cooperative group strategies for assessing optimal approaches in early-stage disease. Clin Cancer Res2007;13:6913s–6920s.
BensonABIII. New approaches to assessing and treating early-stage colon and rectal cancers: cooperative group strategies for assessing optimal approaches in early-stage disease. Clin Cancer Res2007;13:6913s–6920s.
)| false
WillettCG, ComptonCC, ShellitoPC, EfirdJT. Selection factors for local excision or abdominoperineal resection of early stage rectal cancer. Cancer1994;73:2716–2720.
WillettCGComptonCCShellitoPCEfirdJT. Selection factors for local excision or abdominoperineal resection of early stage rectal cancer. Cancer1994;73:2716–2720.
)| false
Van CutsemE, NordlingerB, AdamR. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer2006;42:2212–2221.
Van CutsemENordlingerBAdamR. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer2006;42:2212–2221.
)| false
YooPS, Lopez-SolerRI, LongoWE, ChaCH. Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab. Clin Colorectal Cancer2006;6:202–207.
YooPSLopez-SolerRILongoWEChaCH. Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab. Clin Colorectal Cancer2006;6:202–207.
)| false
AlbertsSR, HorvathWL, SternfeldWC. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol2005;23:9243–9249.
AlbertsSRHorvathWLSternfeldWC. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol2005;23:9243–9249.
)| false
TsaiM, SuY, HoM. Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastases. Ann Surg Oncol2007;14:786–794.
TsaiMSuYHoM. Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastases. Ann Surg Oncol2007;14:786–794.
)| false
PoultsidesGA, ServaisEL, SaltzLB. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol2009;27:3379–3384.
PoultsidesGAServaisELSaltzLB. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol2009;27:3379–3384.
)| false
StanglR, Altendorf-HofmannA, CharnleyRM, ScheeleJ. Factors influencing the natural history of colorectal liver metastases. Lancet1994;343:1405–1410.
StanglRAltendorf-HofmannACharnleyRMScheeleJ. Factors influencing the natural history of colorectal liver metastases. Lancet1994;343:1405–1410.
)| false
ChotiMA, SitzmannJV, TiburiMF. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg2002;235:759–766.
ChotiMASitzmannJVTiburiMF. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg2002;235:759–766.
)| false
PawlikTM, PoonRT, AbdallaEK. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg2005;140:450–457; discussion 457–458.
PawlikTMPoonRTAbdallaEK. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg2005;140:450–457; discussion 457–458.
)| false
CharnsangavejC, ClaryB, FongY. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol2006;13:1261–1268.
CharnsangavejCClaryBFongY. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol2006;13:1261–1268.
)| false
PozzoC, BassoM, CassanoA. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol2004;15:933–939.
PozzoCBassoMCassanoA. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol2004;15:933–939.
)| false
Altendorf-HofmannA, ScheeleJ. A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma. Surg Oncol Clin N Am2003;12:165–192.
Altendorf-HofmannAScheeleJ. A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma. Surg Oncol Clin N Am2003;12:165–192.
)| false
FolprechtG, GrotheyA, AlbertsS. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol2005;16:1311–1319.
FolprechtGGrotheyAAlbertsS. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol2005;16:1311–1319.
)| false
ReddySK, PawlikTM, ZorziD. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol2007;14:3481–3491.
ReddySKPawlikTMZorziD. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol2007;14:3481–3491.
)| false
CoveyAM, BrownKT, JarnaginWR. Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg2008;247:451–455.
CoveyAMBrownKTJarnaginWR. Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg2008;247:451–455.
)| false
AbdallaEK. Commentary: radiofrequency ablation for colorectal liver metastases: do not blame the biology when it is the technology. Am J Surg2009;197:737–739.
AbdallaEK. Commentary: radiofrequency ablation for colorectal liver metastases: do not blame the biology when it is the technology. Am J Surg2009;197:737–739.
)| false
AbdallaEK, VautheyJN, EllisLM. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg2004;239:818–825.
AbdallaEKVautheyJNEllisLM. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg2004;239:818–825.
)| false
HurH, KoYT, MinBS. Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg2009;197:728–736.
HurHKoYTMinBS. Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg2009;197:728–736.
)| false
LeonardGD, BrennerB, KemenyNE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol2005;23:2038–2048.
LeonardGDBrennerBKemenyNE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol2005;23:2038–2048.
)| false
BenoistS, BrouquetA, PennaC. Complete response of colorectal liver metastases after chemotherapy: does it mean cure?J Clin Oncol2006;24:3939–3945.
BenoistSBrouquetAPennaC. Complete response of colorectal liver metastases after chemotherapy: does it mean cure?J Clin Oncol2006;24:3939–3945.
)| false
AdamR, AvisarE, AricheA. Five-year survival following hepatic resecton after neoadjuvant therapy for nonresectable colorectal cancer. Ann Surg Oncol2001;8:347–353.
AdamRAvisarEAricheA. Five-year survival following hepatic resecton after neoadjuvant therapy for nonresectable colorectal cancer. Ann Surg Oncol2001;8:347–353.
)| false
RivoireM, De CianF, MeeusP. Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer2002;95:2283–2292.
RivoireMDe CianFMeeusP. Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer2002;95:2283–2292.
)| false
VautheyJN, PawlikTM, RiberoD. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol2006;24:2065–2072.
VautheyJNPawlikTMRiberoD. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol2006;24:2065–2072.
)| false
PawlikTM, ScogginsCR, ZorziD. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg2005;241:715–722.
PawlikTMScogginsCRZorziD. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg2005;241:715–722.
)| false
EliasD, LiberaleG, VernereyD. Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol2005;12:900–909.
EliasDLiberaleGVernereyD. Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol2005;12:900–909.
)| false
AdamR, DelvartV, PascalG. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg2004;240:644–657.
AdamRDelvartVPascalG. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg2004;240:644–657.
)| false
NordlingerB, SorbyeH, GlimeliusB. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomized controlled trial. Lancet2008;37:1007–1016.
NordlingerBSorbyeHGlimeliusB. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomized controlled trial. Lancet2008;37:1007–1016.
)| false
TanBR, ZubalB, Hawkinsw. Preoperative FOLFOX plus cetuximab or panitumumab therapy for patients with potentially resectable hepatic colorectal metastases [abstract]. Prestented at the 2009 ASCO Gastrointestinal Cancers Symposium; January 15–17, 2009; San Francisco, California. Abstract 497.
TanBRZubalBHawkinsw. Preoperative FOLFOX plus cetuximab or panitumumab therapy for patients with potentially resectable hepatic colorectal metastases [abstract]. Prestented at the 2009 ASCO Gastrointestinal Cancers Symposium; January 15–17, 2009; San Francisco, California. Abstract 497.
)| false
FolprechtG, GruenbergerT, HartmannJT. Cetuximab plus FOLFOX6 or cetuximab plus FOLFIRI as neoadjuvant treatment of nonresectable colorectal liver metastases: A randomized multicenter study (CELIM-study) [abstract]. Presented at the 2009 ASCO Gastrointestinal Cancers Symposium; January 15–17 2009; San Francisco, California. Abstract 296.
FolprechtGGruenbergerTHartmannJT. Cetuximab plus FOLFOX6 or cetuximab plus FOLFIRI as neoadjuvant treatment of nonresectable colorectal liver metastases: A randomized multicenter study (CELIM-study) [abstract]. Presented at the 2009 ASCO Gastrointestinal Cancers Symposium; January 15–17 2009; San Francisco, California. Abstract 296.
)| false
SouglakosJ, AndroulakisN, SyrigosK. FOLFOXIRI vs FOLFIRI as first-line treatment in metastatic colorectal cancer: a multicentre randomised phase III trial from the Hellenic Oncology Research Group. Br J Cancer2006;94:798–805.
SouglakosJAndroulakisNSyrigosK. FOLFOXIRI vs FOLFIRI as first-line treatment in metastatic colorectal cancer: a multicentre randomised phase III trial from the Hellenic Oncology Research Group. Br J Cancer2006;94:798–805.
)| false
FalconeA, RicciS, BrunettiI. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol2007;25:1670–1676.
FalconeARicciSBrunettiI. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol2007;25:1670–1676.
)| false
ReddySK, MorseMA, HurwitzHI. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg2008;206:96–106.
ReddySKMorseMAHurwitzHI. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg2008;206:96–106.
)| false
LeeWS, YunSH, ChunHK. Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival. Int J Colorectal Dis2007;22:699–704.
LeeWSYunSHChunHK. Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival. Int J Colorectal Dis2007;22:699–704.
)| false
HeadrickJR, MillerDL, NagorneyDM. Surgical treatment of hepatic and pulmonary metastases from colon cancer. Ann Thorac Surg2001;71:975–979; discussion 979–980.
HeadrickJRMillerDLNagorneyDM. Surgical treatment of hepatic and pulmonary metastases from colon cancer. Ann Thorac Surg2001;71:975–979; discussion 979–980.
)| false
KemenyN, HuangY, CohenAM. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med1999;341:2039–2048.
KemenyNHuangYCohenAM. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med1999;341:2039–2048.
)| false
YuT-K, BhosalePR, CraneCH. Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer. Int J Rad Oncol Biol Phys2008;71:1175–1180.
YuT-KBhosalePRCraneCH. Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer. Int J Rad Oncol Biol Phys2008;71:1175–1180.
)| false
PelosiE, DeandreisD. The role of 18F-fluoro-deoxy-glucose positron emission tomography (FDG-PET) in the management of patients with colorectal cancer. Eur J Surg Oncol2007;33:1–6.
PelosiEDeandreisD. The role of 18F-fluoro-deoxy-glucose positron emission tomography (FDG-PET) in the management of patients with colorectal cancer. Eur J Surg Oncol2007;33:1–6.
)| false
DresenRC, GosensMJ, MartijnH. Radical resection after IORT-containing multimodality treatment is the most important determinant of outcome in patients with locally recurrent rectal cancer. Ann Surg Oncol2008;15:1937–1947.
DresenRCGosensMJMartijnH. Radical resection after IORT-containing multimodality treatment is the most important determinant of outcome in patients with locally recurrent rectal cancer. Ann Surg Oncol2008;15:1937–1947.
)| false
YanTD, BlackD, SavadyR, SugarbakerPH. Systemic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol2006;24:4011–4019.
YanTDBlackDSavadyRSugarbakerPH. Systemic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol2006;24:4011–4019.
)| false
EsquivelJ, SticcaR, SugarbakerP. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol2007;14:128–133.
EsquivelJSticcaRSugarbakerP. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol2007;14:128–133.
)| false
DeSnooL, FaithfullS. A qualitative study of anterior resection syndrome: the experiences of cancer survivors who have undergone resection surgery. Eur J Cancer Care2006;15:244–251.
DeSnooLFaithfullS. A qualitative study of anterior resection syndrome: the experiences of cancer survivors who have undergone resection surgery. Eur J Cancer Care2006;15:244–251.
)| false
DignamJL, PoliteBN, YothersG. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst2006;98:1647–1654.
DignamJLPoliteBNYothersG. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst2006;98:1647–1654.
)| false
MeyerhardtJA, HeseltineD, NiedzwieckiD. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol2006;24:3535–3541.
MeyerhardtJAHeseltineDNiedzwieckiD. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol2006;24:3535–3541.
)| false
MeyerhardtJA, NiedzwieckiD, HollisD. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA2007;298:754–764.
MeyerhardtJANiedzwieckiDHollisD. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA2007;298:754–764.
)| false
